ConductScience.org, home

Paper11057794

Pharmacokinetics and dosing regimen of meropenem in critically ill patients receiving continuous venovenous hemofiltration.

Ververs TF and 6 others. Crit Care Med, 2000. Cited by 62 papers, by iCite.

Cite this record

ConductScience Library. Pharmacokinetics and dosing regimen of meropenem in critically ill patients receiving continuous venovenous hemofiltration. Papers, record 11057794. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/11057794

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Pharmacokinetics and dosing regimen of meropenem in critically ill patients receiving continuous venovenous hemofiltration.
PubMed
Journal
Crit Care Med
PubMed
Year
2000
PubMed
Publication types
Clinical Trial, Controlled Clinical Trial, Journal Article
PubMed
Citations, by iCite
62
iCite
Relative citation ratio, by iCite
2.3
iCite
Revised in PubMed
2022-04-08
PubMed

Authors7

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Ververs TFT F
2van Dijk AA
3Vinks SAS A
4Blankestijn PJP J
5Savelkoul JFJ F
6Meulenbelt JJ
7Boereboom FTF T

Source PubMed

Download CSV of authors

Topics18

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Acute Kidney InjuryMajor topic
Bacterial InfectionsMajor topic
HemofiltrationMajor topic
ThienamycinsMajor topic
Adult
Critical Illness
Drug Monitoring
Female
Humans
Infusions, Intravenous
Least-Squares Analysis
Male
Meropenem
Metabolic Clearance Rate
Middle Aged
Prospective Studies
Time Factors
Tissue Distribution

Source PubMed

Download CSV of topics

Comments and corrections1

PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.

KindPMIDTitleIn Papers
Comment in11505159Meropenem and continuous renal replacement.https://conductscience.org/library/papers/11505159

Source PubMed

Download CSV of comments and corrections

Cited by23

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 62 citations.

PMIDTitleJournalYearIn PapersSource
42730518Integrating CRRT as a Virtual Organ Into Physiologically Based Pharmacokinetic Modeling to Optimize Antimicrobial Dosing in Septic Patients.CPT Pharmacometrics Syst Pharmacol2026https://conductscience.org/library/papers/42730518PubMed
41792368Development and validation of a machine learning model for individualised meropenem dosing in CRRT patients.Sci Rep2026https://conductscience.org/library/papers/41792368PubMed
36005753Population Pharmacokinetic Meta-Analysis and Dosing Recommendation for Meropenem in Critically Ill Patients Receiving Continuous Renal Replacement Therapy.Antimicrob Agents Chemother2022https://conductscience.org/library/papers/36005753PubMed
34773921Meropenem pharmacokinetics in critically ill patients with or without burn treated with or without continuous veno-venous haemofiltration.Br J Clin Pharmacol2022https://conductscience.org/library/papers/34773921PubMed
32323030Acute-on-chronic liver failure alters meropenem pharmacokinetics in critically ill patients with continuous hemodialysis: an observational study.Ann Intensive Care2020https://conductscience.org/library/papers/32323030PubMed
32046092Drug Dosing Considerations in Critically Ill Patients Receiving Continuous Renal Replacement Therapy.Pharmacy (Basel)2020https://conductscience.org/library/papers/32046092PubMed
31814045The pharmacokinetics of meropenem and piperacillin-tazobactam during sustained low efficiency haemodiafiltration (SLED-HDF).Eur J Clin Pharmacol2020https://conductscience.org/library/papers/31814045PubMed
31157005Individualised antimicrobial dosing in critically ill patients undergoing continuous renal replacement therapy: focus on total drug clearance.Eur J Hosp Pharm2018https://conductscience.org/library/papers/31157005PubMed
30094712A Robust Statistical Approach to Analyse Population Pharmacokinetic Data in Critically Ill Patients Receiving Renal Replacement Therapy.Clin Pharmacokinet2019https://conductscience.org/library/papers/30094712PubMed
26997934Pharmacokinetics of Continuous Infusion Meropenem With Concurrent Extracorporeal Life Support and Continuous Renal Replacement Therapy: A Case Report.J Pediatr Pharmacol Ther2016https://conductscience.org/library/papers/26997934PubMed
25881576A multicenter study on the effect of continuous hemodiafiltration intensity on antibiotic pharmacokinetics.Crit Care2015https://conductscience.org/library/papers/25881576PubMed
25042938Beta-lactam dosing in critically ill patients with septic shock and continuous renal replacement therapy.Crit Care2014https://conductscience.org/library/papers/25042938PubMed
24886826β-lactam antibiotic concentrations during continuous renal replacement therapy.Crit Care2014https://conductscience.org/library/papers/24886826PubMed
23675445Inhibitor discovery of full-length New Delhi metallo-β-lactamase-1 (NDM-1).PLoS One2013https://conductscience.org/library/papers/23675445PubMed
22839761Does Beta-lactam Pharmacokinetic Variability in Critically Ill Patients Justify Therapeutic Drug Monitoring? A Systematic Review.Ann Intensive Care2012https://conductscience.org/library/papers/22839761PubMed
21649882Recommended β-lactam regimens are inadequate in septic patients treated with continuous renal replacement therapy.Crit Care2011https://conductscience.org/library/papers/21649882PubMed
21343897Antibiotic dosing in critically ill patients with acute kidney injury.Nat Rev Nephrol2011https://conductscience.org/library/papers/21343897PubMed
20479205Meropenem dosing in critically ill patients with sepsis receiving high-volume continuous venovenous hemofiltration.Antimicrob Agents Chemother2010https://conductscience.org/library/papers/20479205PubMed
19040780Clinical review: Drug metabolism and nonrenal clearance in acute kidney injury.Crit Care2008https://conductscience.org/library/papers/19040780PubMed
18307371Population pharmacokinetics of meropenem in critically ill patients undergoing continuous renal replacement therapy.Clin Pharmacokinet2008https://conductscience.org/library/papers/18307371PubMed

See all 23 cited byDownload CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • References
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/11057794

GET https://conductscience.org/api/papers/v1/11057794/cited_by?page=2